Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Brief Communication

Neutralizing antibody responses to SARS-CoV-2: A population based seroepidemiological analysis

Pragya Sharma a, Ekta Guptab, Saurav Basua,c, Reshu Agarwal b, Suruchi Mishra a,*
Pratibha Kale b, Nutan Mundejad, B.S. Charand, Gautam Kumar Singhd, M.M. Singha

a Department of Community Medicine, Maulana Azad Medical College, New Delhi, India
b Department of Clinical Virology, Institute of Liver and Biliary Sciences, New Delhi, India
c Indian Institute of Public Health – Delhi, Public Health Foundation of India, New Delhi, India
d Directorate General Health Services, Government of NCT, New Delhi, India

ARTICLE INFO

Keywords:
SARS-CoV-2
Anti-SARS-CoV-2 neutralizing antibody
Vaccination
Covid-19

ABSTRACT

This study (August–September 2021) estimated the seroprevalence of SARS-CoV-2 neutralizing antibodies in the general population of Delhi and correlated it with their anti-SARS-CoV-2 IgG levels. Samples were selected by simple random sampling method. The neutralizing capacity was estimated by performing a surrogate virus neutralization test (sVNT) (GenScript), Piscataway, NJ, USA.

A total of 2233 (87.1%, 95% C.I. 85.7, 88.3) of the 2564 SARS-CoV-2 IgG seropositive samples had detectable SARS-CoV-2 neutralizing antibodies. In samples with S/CO ≥ 4.00, the neutralizing antibodies ranged from 94.5% to 100%. The SARS-CoV-2 neutralizing antibody seroprevalence strongly correlated with the S/CO range of IgG SARS-CoV-2 (r = 0.62, p = 0.002).

1. Introduction

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic with enormous morbidity, mortality, and economic losses. India has till date recorded 34,633,255 cases and 473,326 deaths [1].

Protection from SARS-CoV-2 infection is accorded from previous infection or vaccination that substantially reduces the risk of symptomatic and severe disease and that of reinfection [2,3]. Neutralizing SARS-CoV-2 antibodies once produced are expected to provide durable and effective protection lasting at least several months afterwards [4].

Several population-based SARS-CoV-2 seroepidemiological studies have been conducted in India but these have usually screened for antibodies recognizing SARS-CoV-2 spike antigens and/or nucleoprotein [5,6]. It is therefore uncertain as to the extent of the population having the protective SARS-CoV-2 neutralization antibodies. A surrogate virus neutralization test (sVNT) is capable of measuring majority of the neutralizing antibodies against SARS-CoV-2 viral spike (S) protein Receptor Binding Domain (RBD) without requirement of the live virus cells [7].

This study was conducted with the objective of estimating the seroprevalence of neutralizing antibodies in the general population and to further correlate it with the anti-SARS-CoV-2 IgG levels.

2. Methods

This present cross-sectional analysis was conducted as a sequel of a state level community-based seroepidemiological study. The anti-SARS-CoV-2 IgG antibodies were screened in the general population of Delhi aged ≥ 5 years that were selected through a two-stage random sampling method from 11 districts spanning 274 wards in Delhi, India. A total of 25,622 (89.5%) of the 27,811 samples had detectable SARS-CoV-2 neutralizing antibodies. In samples with S/CO ≥ 4.00, the neutralizing antibodies ranged from 94.5% to 100%. The SARS-CoV-2 neutralizing antibody seroprevalence strongly correlated with the S/CO range of IgG SARS-CoV-2 (r = 0.62, p = 0.002).

* Corresponding author. Dr. Suruchi Mishra, Room No. 358, Department of Community Medicine, Maulana Azad Medical College, 2 BSZ Marg, New Delhi – 110002, India.
E-mail address: drsuruchimishramamc@gmail.com (S. Mishra).

https://doi.org/10.1016/j.ijmmb.2022.07.009
Received 14 February 2022; Received in revised form 15 July 2022; Accepted 16 July 2022
Available online 8 August 2022
0255-0857/© 2022 Indian Association of Medical Microbiologists. Published by Elsevier B.V. All rights reserved.
screened for the SARS-CoV-2 neutralization antibodies. The samples were selected through computer-based simple random sampling method and the sample size was adequate at 95% confidence levels with 1.2% absolute precision. Neutralizing capacity was estimated by performing a surrogate virus neutralization test (sVNT) (GenScript, Piscataway, NJ, USA) having a specificity of 93.8% and sensitivity of 99.4% as per manufacturer instructions. This sVNT assay uses purified RBD from the SARS-CoV-2 viral spike (S) protein and the host cell receptor ACE2 that purposively mimics the virus-host interaction [7,10].

Neutralizing antibodies to SARS-CoV-2 was operationally considered as detected when the signal inhibition was >30%. Data were analysed with IBM SPSS Statistics for Windows, Version 25.0. Armonk, NY: IBM Corp. To estimate the seroprevalence of the anti-SARS-CoV-2 neutralizing antibodies in the general population of Delhi, the formula used was: Estimated number of cases with anti-SARS-CoV-2 neutralizing antibodies = 100/(Total number of cases in the serosurvey). Since, 10% of seropositive samples were tested for the presence of neutralizing antibodies, this seroprevalence fraction was extrapolated to the complete IgG serosurvey sample (n = 25,622). The denominator included total number of cases in the serosurvey sample inclusive of both IgG SARS-CoV-2 seropositive (n = 25,622) and IgG SARS-CoV-2 seronegative participants (n = 2189). The chi-square test was used to find the association between the independent variables (age, sex, Diabetes, Hypertension) and the dependent variable (anti-SARS-CoV-2 neutralizing antibody). A p-value < 0.05 was considered statistically significant.

The study was approved by the Institutional Ethics Committee F.1/IEC/MAMC/85/03/2021/No428 dated 21.08.2021. Adult participants provided informed electronic consent, while minor participants provided parent’s consent and informed electronic assent.

3. Results and discussion

A total of 2233 (87.1%, 95% CI 85.7, 88.3%) of the 2564 SARS-CoV-2 seropositive samples had detectable anti-SARS-CoV-2 neutralizing antibodies. The anti-SARS-CoV-2 neutralizing antibody seropositivity in the serosurvey sample on extrapolating the findings from this study was estimated as 80.2%.

On bivariate analysis but not on adjusted analysis, Covid-19 vaccination showed a statistically significant association with the presence of these neutralizing antibodies (p < 0.001). However, age, sex, diabetes or HTN comorbidity were not independently associated with the presence of neutralizing antibodies (Table 1).

The signal/cut off ratio (S/CO) of anti-SARS-CoV-2 IgG ranged from 1.00 to 22.8 (median 11.40). In cases with S/CO ratio between 1 and 1.99 (n = 432), anti-SARS-CoV-2 neutralization antibodies were observed in 232 (52%) while in those cases having S/CO ratio between 2 and 2.99 (n = 309), the anti-SARS-CoV-2 neutralization antibodies were observed in 237 (76.7%) cases. Furthermore, in the cases with S/CO ratio between 3 and 3.99 (n = 111), anti-SARS-CoV-2 neutralization antibodies were observed in 88 (79.2%). Among the samples with S/CO ≥ 4.00 (n = 1698), the prevalence of neutralizing antibodies ranged from 94.5 to 100%, while in samples with S/CO < 4.00 (n = 535), it ranged from 52.0 to 79.2%. The anti-SARS-CoV-2 neutralizing antibody seroprevalence strongly correlated with the S/CO range of anti-SARS-CoV-2 IgG (r = 0.62, p = 0.002). Previous studies have suggested that SARS-CoV-2 neutralizing antibodies are able to block the viral infection and provide durable immune response despite the likelihood of waning of overall antibody levels. A large-scale study at Mount Sinai hospital, USA among health care workers also found strong correlation of IgG antibody responses against the viral spike protein generated in those with natural SARS-CoV-2 infection [11]. Our study results indicate that in populations with high SARS-CoV-2 seroprevalence with either infection or vaccine induced immune response, neutralizing antibodies are generated in nearly 9 of 10 seropositive individuals, with no statistically significant variation in the observed risk based on the individuals’ age, sex, and comorbidity status.

This study also suggests that a higher signal to cut-off ratio may be considered as an indirect marker for the presence of neutralizing antibody response. This finding may have a clinical implication towards recommending booster doses in vulnerable populations like the immunocompromised and healthcare workers.

Certain variants of concern especially the Delta have demonstrated the ability to bypass existing immune response and elicit symptomatic disease even in vaccinated and more rarely in recovered individuals [12]. However, in this study, vaccination with at-least one dose of vaccine, either CHADOX1 NCOV-19 (Covishield) or BBV152 (Covaxin) was likely to induce robust neutralizing antibody response. Evidence from mostly in-vitro studies also indicate that neutralization titres highly correlate with protection against the SARS-CoV-2 variants of concern with waning of antibodies predictive of rapid loss of protection, which can be restored through booster vaccination [13].

Study limitations were that the entire IgG seropositive cohort from the serosurvey were not examined for anti-SARS-CoV-2 neutralizing antibodies due to resource limitations. Nevertheless, the representative and adequately powered sample size enable generalization of the study findings to the general population of Delhi.

Author contribution statement

Pragya Sharma and Ekta Gupta: Conceptualization.
Pragya Sharma, Ekta Gupta, Suruchi Mishra: Data curation.
Ekta Gupta and Saurav Basu: Formal analysis.
Pragya Sharma, Suruchi Mishra, Ekta Gupta, Reshu Agarwal: Investigation.
All authors: Methodology.
Pragya Sharma, MM Singh, Ekta Gupta, Nutan Mundeha, Gautam K Singh: Resources.
Ekta Gupta and Suruchi Mishra: Supervision;
Pragya Sharma: Ekta Gupta, Reshu Agarwal, Pratibha Kale: Validation.
All authors provided final approval of the version to be submitted.
Saurav Basu: Writing - original draft;
All authors contributed to writing - review & editing.

Preprint

MEDRXIV https://doi.org/10.1101/2021.12.28.21268472.
Sources of funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. The logistics and human resources were assigned by the Directorate General of Health Services, government of the National Capital Territory, Delhi and supported by the ATE Chandra Foundation and ACT grants.

Conflicts of interest

None.

Declaration of competing interest

All authors have seen and approved the final version of the manuscript being submitted. They warrant that the article is the authors' original work, hasn’t received prior publication and isn't under consideration for publication elsewhere.

References

[1] John Hopkins Coronavirus Tracker. Available from: https://coronavirus.jhu.edu/map.html. [Accessed 5 December 2021].

[2] Suthar MS, Zimmerman MG, Kauffman RC, Mantus G, Lindenman SL, Hudson WH, et al. Rapid generation of neutralizing antibody responses in COVID-19 patients. Cell Rep Med 2020;1(3):100040. https://doi.org/10.1016/j.xcrm.2020.100040.

[3] Edara VV, Hudson WH, Xie X, Ahmed R, Suthar MS. Neutralizing antibodies against SARS-CoV-2 variants after infection and vaccination. JAMA 2021;325(18):1896–8. https://doi.org/10.1001/jama.2021.4388.

[4] Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Falliti CE, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science 2021; 371(6529):eabc4063. https://doi.org/10.1126/science.abc4063.

[5] Murhekar MV, Bhatnagar T, Selvaraju S, Rade K, Saravanakumar V, Thangaraj JWV, et al. Prevalence of SARS-CoV-2 infection in India: findings from the national serosurvey, May-Jun 2020. Indian J Med Res 2020;152:46–60.

[6] Sharma N, Sharma P, Basu S, Bakshi R, Gupta E, Agarwal R, et al. Second wave of the COVID-19 pandemic in Delhi, India: high seroprevalence not a deterrent? Cureus 2021;13(10):e19000. https://doi.org/10.7759/cureus.19000.

[7] Tan CW, Chia WN, Qin X, Liu P, Chen MI, Tiu C, et al. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockade of ACE2-spike protein-protein interaction. Nat Biotechnol 2020;38(9):1073–8. https://doi.org/10.1038/s41587-020-0631-z.

[8] Instructions for use - CoV2G. VITROS. Available from: https://www.fda.gov/media/137363/download. [Accessed 5 December 2021].

[9] Sharma P, Basu S, Mishra S, Gupta E, Aggarwal R, Kade F, et al. SARS-CoV-2 seroprevalence in Delhi, India - September-October 2021 - a population based seroepidemiological study. medRxiv 2021;12(28):21268451. https://doi.org/10.1101/2021.12.28.21268451.

[10] GenScript. SARS-CoV-2 Surrogate Virus Neutralization Test (sVNT) Kit (RUO). Available from: https://www.genscript.com/covid-19-detection-svnt.html. [Accessed 5 December 2021].

[11] Wajnberg A, Amanat F, Firpo A, Altman DR, Bailey MJ, Mansour M, et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science 2020; 370(6521):1227–30. https://doi.org/10.1126/science.abc7728.

[12] Planas D, Veyer D, Baidaliuk A, Staropoli I, Guivel-Benhassine F, Rajah MM, et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature 2021;596(7871):276–80. https://doi.org/10.1038/s41586-021-03777-9.

[13] Cromer D, Steain M, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis. Lancet Microbe 2022;3(1):e52–61. https://doi.org/10.1016/S2666-5247(21)00267-6.